Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Recurrent Acute Undifferentiated Leukemia: early-phase trial registry

2 of 2 indexed Recurrent Acute Undifferentiated Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Recurrent Acute Undifferentiated Leukemia: 2 US clinical trials tracked, 2 recruiting.

Recurrent Acute Undifferentiated Leukemia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition recurrent-acute-undifferentiated-leukemia

OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Recurrent Acute Undiffer (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Recurrent Acute Undifferentiated Leukemia

Recurrent Acute Undifferentiated Leukemia lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Acute Undifferentiated Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Acute Undifferentiated Leukemia is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Named interventions

Most-linked intervention names on Recurrent Acute Undifferentiated Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bone Marrow Aspiration Procedure
2 trials
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR Biological
1 trials
Cytarabine Drug
1 trials
Chest Radiography Procedure
1 trials
Decitabine Drug
1 trials
Bone Marrow Biopsy Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Recurrent Acute Undifferentiated Leukemia trials. A trial with sites in several states counts in each.

Washington 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Acute Undifferentiated Leukemia page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Recurrent Acute Undifferentiated Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Fred Hutchinson Cancer Center sponsors the most Recurrent Acute Undifferentiated Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Acute Undifferentiated Leukemia condition card totals 2 registered trials; most-linked intervention Bone Marrow Aspiration; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.